Citigroup
STOK icon

Citigroup’s Stoke Therapeutics STOK Stock Holding History

Citigroup’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Buy
69,326
+56,600
+445% +$1.82M ﹤0.01% 2836
2026
Q1 		$414K Sell
12,726
-877
-6% -$28.8K ﹤0.01% 3654
2025
Q4 		$432K Buy
13,603
+7,088
+109% +$213K ﹤0.01% 3642
2025
Q3 		$153K Sell
6,515
-19,715
-75% -$338K ﹤0.01% 4101
2025
Q2 		$298K Sell
26,230
-48,390
-65% -$459K ﹤0.01% 3881
2025
Q1 		$496K Buy
74,620
+16,487
+28% +$154K ﹤0.01% 3683
2024
Q4 		$641K Buy
58,133
+32,467
+126% +$399K ﹤0.01% 3653
2024
Q3 		$315K Buy
25,666
+10,522
+69% +$149K ﹤0.01% 4043
2024
Q2 		$205K Buy
15,144
+9,678
+177% +$131K ﹤0.01% 3859
2024
Q1 		$73.8K Buy
5,466
+1,494
+38% +$9.05K ﹤0.01% 4432
2023
Q4 		$20.9K Buy
3,972
+3,372
+562% +$14.4K ﹤0.01% 4974
2023
Q3 		$2.36K Sell
600
-8,868
-94% -$58.3K ﹤0.01% 4917
2023
Q2 		$101K Buy
9,468
+8,623
+1,020% +$91.7K ﹤0.01% 4246
2023
Q1 		$7.04K Sell
845
-197
-19% -$1.78K ﹤0.01% 4853
2022
Q4 		$9.62K Sell
1,042
-152
-13% -$1.58K ﹤0.01% 4852
2022
Q3 		$15K Sell
1,194
-1,434
-55% -$22.9K ﹤0.01% 4854
2022
Q2 		$35K Sell
2,628
-17,932
-87% -$272K ﹤0.01% 4697
2022
Q1 		$433K Sell
20,560
-34,234
-62% -$686K ﹤0.01% 3610
2021
Q4 		$1.31M Buy
54,794
+14,927
+37% +$356K ﹤0.01% 2977
2021
Q3 		$1.01M Sell
39,867
-28,749
-42% -$802K ﹤0.01% 3074
2021
Q2 		$2.31M Buy
68,616
+24,679
+56% +$872K ﹤0.01% 2559
2021
Q1 		$1.71M Buy
43,937
+40,015
+1,020% +$2.28M ﹤0.01% 2601
2020
Q4 		$243K Buy
3,922
+1,076
+38% +$49.3K ﹤0.01% 4846
2020
Q3 		$95K Sell
2,846
-2,900
-50% -$82.8K ﹤0.01% 5163
2020
Q2 		$137K Sell
5,746
-1,446
-20% -$34.3K ﹤0.01% 5311
2020
Q1 		$165K Buy
7,192
+2,800
+64% +$69.2K ﹤0.01% 4900
2019
Q4 		$124K Buy
4,392
+3,985
+979% +$100K ﹤0.01% 5569
2019
Q3 		$9K Buy
+407
New +$11.3K ﹤0.01% 7138

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's STOK Position: Q2 2026 in Review

Citigroup increased its Stoke Therapeutics (STOK) stake by 445% in Q2 2026, buying an estimated $1.82M and bringing the position to 69,326 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2836.

Citigroup first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.31M in Q2 2021. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Citigroup held 69,326 shares of Stoke Therapeutics worth $2.27M as of Q2 2026.
  • Citigroup bought 56,600 Stoke Therapeutics shares in Q2 2026, an estimated $1.82M.
  • Stoke Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2836 holding.
  • Citigroup first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Stoke Therapeutics position peaked at $2.31M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.